相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The North America prefilled syringes market is valued at USD 6.26 billion in 2025 and is projected to reach USD 17.46 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035. - Growth is driven by rising chronic disease prevalence, an aging population, increasing use of complex biologic drugs, and strong preference for self-administered injectable treatments at home. - Conventional prefilled syringes held a 62.00% share in 2025, while glass dominated the material segment at 78.00%, and diabetes led applications at 28.00%. - Key players including BD, Gerresheimer, SCHOTT Pharma, and West Pharmaceutical Services lead the market with specialized glass and polymer syringe systems.
- SCHOTT Pharma introduces the smallest sterile ready-to-use cartridge at 1.5 ml, expanding its cartriQ portfolio for insulin, GLP-1 drugs, and hormone therapies. - The new format, featuring an optimized diamond-shaped nest design, boosts pharmaceutical filling efficiency by up to 67% and reduces supply chain CO2 emissions by nearly 25%. - The cartridge is compatible with a broad range of pen injectors, including Ypsomed's UnoPen, supporting the shift toward self-administration and homecare for chronic diseases. - The launch aligns with SCHOTT Pharma's strategy to deliver high-value RTU solutions that reduce total cost of ownership and accelerate time-to-market for pharmaceutical partners.
- SCHOTT Pharma announced a €100 million ($114 million) investment to increase production capacity for ready-to-use sterile cartridges used in injectable medications. - The expansion targets growing pharmaceutical sector demand for pre-filled drug delivery systems that simplify administration while maintaining sterility and safety standards. - The investment reflects an industry-wide trend toward pre-filled solutions that improve efficiency and reduce contamination risks in drug delivery systems. - SCHOTT Pharma currently serves over 1,800 customers including the top 30 leading pharmaceutical manufacturers for injectable drugs, generating €957 million in revenue in fiscal year 2024.
• US private equity firm TPG, along with co-investor Novo Holdings, has agreed to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India (SII) for approximately $300 million, with the deal expected to close in the first half of 2025. • SCHOTT Poonawalla, India's largest injectables-focused drug containment solutions company, will maintain its existing structure with SCHOTT Pharma retaining 50% ownership while SII will keep a minority stake following the transaction. • The strategic partnership aims to accelerate SCHOTT Poonawalla's global expansion by combining TPG's healthcare investment expertise with the company's advanced drug delivery solutions portfolio, which includes prefillable syringes, cartridges, and vials for biologics and vaccines.
